SAS said that it will support the redesign of clinical and patient data flow by delivering analytics and AI, manage changing trial designs, enable data re-use, and help accelerate reporting and submission timelines. It will also deliver increased capacity, automation, interoperability, and flexibility to bring in and analyze diverse and novel patient data sources – such as those coming from wearables, sensors and precision medicine – as part of AstraZeneca’s submissions process.

The analysis and reporting phases will be supported with SAS Life Science Analytics Framework and SAS Viya, SAS’s cloud-based industry platform. This has the potential to provide significant productivity gains by driving faster time to market and reduced IT costs. The collaboration between SAS and AstraZeneca is designed to enable teams within the Anglo-Swedish drugmaker to work together and drive innovation in clinical research.

Christopher J. Miller, vice president Biometrics at AstraZeneca, said: “This partnership with SAS supports the transformation of how we use clinical data to support our patient-centric approach and focus on getting medicines to patients faster than ever before. It will also allow us to introduce new ways of working and embrace new technologies and trial models to accelerate our portfolio.”

“I’m delighted that SAS is building on the strong relationship it has had with AstraZeneca over many years by being part of this transformation program. The work they do positively impacts the lives of millions of people around the world,” added Bryan Harris, SAS executive vice president and chief technology officer.